GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Intelligent Medicine Acquisition Corp (NAS:IQMDU) » Definitions » EV-to-FCF

Intelligent Medicine Acquisition (Intelligent Medicine Acquisition) EV-to-FCF : -379.73 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Intelligent Medicine Acquisition EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Intelligent Medicine Acquisition's Enterprise Value is $258.60 Mil. Intelligent Medicine Acquisition's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.68 Mil. Therefore, Intelligent Medicine Acquisition's EV-to-FCF for today is -379.73.

The historical rank and industry rank for Intelligent Medicine Acquisition's EV-to-FCF or its related term are showing as below:

IQMDU' s EV-to-FCF Range Over the Past 10 Years
Min: -95.22   Med: 0   Max: 0
Current: -95.22

IQMDU's EV-to-FCF is not ranked
in the Diversified Financial Services industry.
Industry Median: 10.2 vs IQMDU: -95.22

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Intelligent Medicine Acquisition's stock price is $10.98. Intelligent Medicine Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $0.000. Therefore, Intelligent Medicine Acquisition's PE Ratio for today is N/A.


Intelligent Medicine Acquisition EV-to-FCF Historical Data

The historical data trend for Intelligent Medicine Acquisition's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Medicine Acquisition EV-to-FCF Chart

Intelligent Medicine Acquisition Annual Data
Trend Dec21 Dec22
EV-to-FCF
- -306.74

Intelligent Medicine Acquisition Quarterly Data
Feb21 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22
EV-to-FCF Get a 7-Day Free Trial - - -1,932.93 -1,137.12 -306.74

Competitive Comparison of Intelligent Medicine Acquisition's EV-to-FCF

For the Shell Companies subindustry, Intelligent Medicine Acquisition's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelligent Medicine Acquisition's EV-to-FCF Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Intelligent Medicine Acquisition's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Intelligent Medicine Acquisition's EV-to-FCF falls into.



Intelligent Medicine Acquisition EV-to-FCF Calculation

Intelligent Medicine Acquisition's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=258.595/-0.681
=-379.73

Intelligent Medicine Acquisition's current Enterprise Value is $258.60 Mil.
Intelligent Medicine Acquisition's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelligent Medicine Acquisition  (NAS:IQMDU) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Intelligent Medicine Acquisition's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.98/0.000
=N/A

Intelligent Medicine Acquisition's share price for today is $10.98.
Intelligent Medicine Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Intelligent Medicine Acquisition EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Intelligent Medicine Acquisition's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelligent Medicine Acquisition (Intelligent Medicine Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
9001 Burdette Road, Bethesda, MD, USA, 20817
Intelligent Medicine Acquisition Corp is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
Executives
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Saba Capital Management, L.p. 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Joseph L Schocken director 2800 UNION SQUARE, 600 UNIVERSITY STREET, SEATTLE WA 98101
Kavita Patel director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jack Hidary director 3 PARK AVENUE, NEW YORK NY 10016
Gregory C Simon director, officer: CEO and CFO 9001 BURDETTE RD., BETHESDA MD 20817
Patience Marime-ball director 9001 BURDETTE RD., BETHESDA MD 20817
Intelligent Medicine Sponsor Llc 10 percent owner 9001 BURDETTE ROAD, BETHESDA MD 20817

Intelligent Medicine Acquisition (Intelligent Medicine Acquisition) Headlines